Teva Pharmaceutical Industries LimitedTEVANYSE

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

globenewswire.com

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the New England Journal of Medicine (NEJM) has published pivotal Phase 3 data on AJOVY, highlighting its efficacy and safety in children and adolescents with episodic migraine. The data from the SPACE study supported the FDA approval of AJOVY for the preventive treatment of episodic migraine in pediatric patients aged 6-17 years weighing 45 kilograms (99 pounds) or more, making it the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for preventive treatment of episodic migraine in pediatric patients and migraine in adults.1,2

seekingalpha.com

Teva Is No Longer A Turnaround Story, It's A Growth One

Teva Pharmaceutical (TEVA) remains a Buy, with specialty drugs, margin expansion, and the Royalty Pharma partnership driving further upside despite a 112% rally. TEVA's specialty pipeline—AUSTEDO, UZEDY, AJOVY—now anchors growth, with Royalty Pharma's $500M backing validating R&D and enabling non-dilutive financing. At under 12x 2026 earnings, TEVA trades below specialty pharma peers; a rerating to 14x could yield 19–30% further upside if execution continues.

seekingalpha.com

Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

benzinga.com

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-‘408.

zacks.com

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug

Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.

barrons.com

Why Investors Are So Optimistic on Teva

Teva Pharmaceuticals stock jumped Monday after the drugmaker issued upbeat guidance and targets for the years ahead.

zacks.com

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

globenewswire.com

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)

globenewswire.com

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026.

globenewswire.com

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).

fool.com

Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story

Prague-based Pale Fire Capital SE added 639,162 shares of Teva in the third quarter. The overall position value increased by $16.53 million from the previous period.

globenewswire.com

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva's long-term issuer credit rating to ‘BB+' from ‘BB', with a stable outlook, and that Moody's Ratings Agency ("Moody's") affirmed Teva's B1a rating and revised Teva's outlook to positive from stable. These upgrades mark another significant milestone in Teva's journey toward achieving investment-grade status.

fool.com

Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026

Quarterly-filed Form 13Fs allow investors to track which stocks Wall Street's savviest money managers are buying and selling. Billionaire Stanley Druckenmiller dumped his fund's stakes in AI darlings Nvidia and Palantir -- and profit-taking may not explain the entire story.

seekingalpha.com

Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)

Teva, the Israeli pharmaceutical giant, is reaching new heights, breaking the $30 mark. The rise in its share price reflects both the strengthening of its balance sheet and the rising sales of Austedo and Ajovy. So, sales of Ajovy totaled $169 million in Q3, up 22.5% year-on-year.

defenseworld.net

Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 52-Week High Following Analyst Upgrade

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA - Get Free Report)'s stock price hit a new 52-week high during trading on Monday after Piper Sandler raised their price target on the stock from $30.00 to $40.00. Piper Sandler currently has an overweight rating on the stock. Teva Pharmaceutical Industries traded as high as $30.98 and last traded

defenseworld.net

Teva Pharmaceutical Industries (NYSE:TEVA) CAO Sells $371,460.00 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA - Get Free Report) CAO Amir Weiss sold 12,300 shares of the business's stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the transaction, the chief accounting officer directly owned 5,650 shares

defenseworld.net

Roberto Mignone Sells 77,400 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA - Get Free Report) Director Roberto Mignone sold 77,400 shares of the firm's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the transaction, the director directly owned 367,600 shares of the company's stock,

globenewswire.com

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. concerning the launch of AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept) in the United States. The settlement grants a license entry date for AVT06 in the United States in the fourth quarter of 2026, or earlier under certain circumstances.

fool.com

My Top 10 Portfolio Holdings for 2026

It's been another banner year on Wall Street, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite, respectively, higher by 14%, 16%, and 20% year-to-date. Although I've been a net seller of stocks in 2025, I'm a long-term investor who intends to hold the majority of my 36 positions for years to come.

zacks.com

Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance